View Exam | PowerPak

1. Which of the following approved indications for pembrolizumab requires tumor proportion score (TPS) to determine PD-L1 expression?

A. Non-small cell lung cancer B. Urothelial carcinoma C. Gastric cancer D. Cervical cancer E. Unsure

2. Which of the following statements is TRUE about combined positive score (CPS)?

A. CPS and tumor proportion score (TPS) use different immunohistochemistry assays B. CPS is a measure based on the number of PD-L1 stained tumor cells, lymphocytes, and macrophages C. CPS is often measured by using fluorescence in-situ hybridization (FISH) D. CPS of 10 or higher is the cutoff for PD-L1 expression E. Unsure

3. Which of the following treatments is currently approved by the United States Food and Drug Administration for microsatellite instability-high (MSI-H) metastatic solid tumors?

A. Nivolumab B. Avelumab C. Atezolizumab D. Pembrolizumab E. Unsure

4. Which of the following is TRUE about total mutation burden (TMB)?

A. TMB is an independent predictor of clinical benefit, regardless of PD-L1 biomarker expression B. Progression-free survival was longer with first-line nivolumab and ipilimumab than with chemotherapy among patients with non-small cell lung cancer and low TMB C. TMB is assessed using immunohistochemistry D. High TMB is defined as at least 8 mutations per megabase E. Unsure

5. Which of the following indications would NOT require PD-L1 testing for single agent pembrolizumab?

A. Non-small cell lung cancer B. Gastric cancer C. Cervical cancer D. Unresectable or metastatic melanoma E. Unsure

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following approved indications for pembrolizumab requires tumor proportion score (TPS) to determine PD-L1 expression?

2. Which of the following statements is TRUE about combined positive score (CPS)?

3. Which of the following treatments is currently approved by the United States Food and Drug Administration for microsatellite instability-high (MSI-H) metastatic solid tumors?

4. Which of the following is TRUE about total mutation burden (TMB)?

5. Which of the following indications would NOT require PD-L1 testing for single agent pembrolizumab?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following approved indications for pembrolizumab requires tumor proportion score (TPS) to determine PD-L1 expression?

2. Which of the following statements is TRUE about combined positive score (CPS)?

3. Which of the following treatments is currently approved by the United States Food and Drug Administration for microsatellite instability-high (MSI-H) metastatic solid tumors?

4. Which of the following is TRUE about total mutation burden (TMB)?

5. Which of the following indications would NOT require PD-L1 testing for single agent pembrolizumab?

« Return to Activity

Customers who Purchased
this Activity also Purchased